On May 18, 2020 Boston Scientific Corporation (NYSE: BSX) reported that it completed a public offering of $1.7 billion aggregate principal amount of its senior notes (Press release, Boston Scientific, MAY 18, 2020, View Source [SID1234558237]). The public offering consists of $500.0 million of 1.900% notes due 2025 and $1.2 billion of 2.650% notes due 2030.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company intends to use the net proceeds from this offering towards (i) refinancing $450.0 million of borrowings under its revolving credit facility and a portion of its pre-payable bank debt, including $750.0 million under its $1.0 billion term loan credit facility maturing in February 2021 and $500.0 million under its $1.25 billion term loan credit facility maturing in April 2021 and (ii) paying related fees, expenses and premiums.